image
Healthcare - Medical - Devices - NYSE - US
$ 320.31
-8.54 %
$ 8.98 B
Market Cap
-11.83
P/E
1. INTRINSIC VALUE

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories.[ Read More ]

The intrinsic value of one BIO stock under the base case scenario is HIDDEN Compared to the current market price of 320 USD, Bio-Rad Laboratories, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BIO

image
FINANCIALS
2.67 B REVENUE
-4.67%
384 M OPERATING INCOME
-20.48%
-637 M NET INCOME
82.43%
375 M OPERATING CASH FLOW
92.83%
20.2 M INVESTING CASH FLOW
101.67%
-426 M FINANCING CASH FLOW
-43.72%
650 M REVENUE
1.76%
64.5 M OPERATING INCOME
-35.72%
653 M NET INCOME
130.16%
164 M OPERATING CASH FLOW
68.19%
-55.6 M INVESTING CASH FLOW
-79.89%
-96.6 M FINANCING CASH FLOW
-0.02%
Balance Sheet Decomposition Bio-Rad Laboratories, Inc.
image
Current Assets 3.05 B
Cash & Short-Term Investments 1.61 B
Receivables 489 M
Other Current Assets 946 M
Non-Current Assets 9.25 B
Long-Term Investments 7.7 B
PP&E 724 M
Other Non-Current Assets 830 M
Current Liabilities 523 M
Accounts Payable 145 M
Short-Term Debt 40.9 M
Other Current Liabilities 337 M
Non-Current Liabilities 3.04 B
Long-Term Debt 1.36 B
Other Non-Current Liabilities 1.67 B
EFFICIENCY
Earnings Waterfall Bio-Rad Laboratories, Inc.
image
Revenue 2.67 B
Cost Of Revenue 1.24 B
Gross Profit 1.43 B
Operating Expenses 1.05 B
Operating Income 384 M
Other Expenses 1.02 B
Net Income -637 M
RATIOS
53.58% GROSS MARGIN
53.58%
14.37% OPERATING MARGIN
14.37%
-23.86% NET MARGIN
-23.86%
-7.29% ROE
-7.29%
-5.18% ROA
-5.18%
2.90% ROIC
2.90%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bio-Rad Laboratories, Inc.
image
Net Income -637 M
Depreciation & Amortization 192 M
Capital Expenditures -157 M
Stock-Based Compensation 61.3 M
Change in Working Capital -128 M
Others 991 M
Free Cash Flow 218 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bio-Rad Laboratories, Inc.
image
Wall Street analysts predict an average 1-year price target for BIO of $400 , with forecasts ranging from a low of $400 to a high of $400 .
BIO Lowest Price Target Wall Street Target
400 USD 24.88%
BIO Average Price Target Wall Street Target
400 USD 24.88%
BIO Highest Price Target Wall Street Target
400 USD 24.88%
4. DIVIDEND ANALYSIS
0.17% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Bio-Rad Laboratories, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
555 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
11 months ago
Dec 12, 2023
Sell 359 K USD
WRIGHT DARA
EVP, President, CDG
- 1200
299.16 USD
11 months ago
Nov 28, 2023
Sell 196 K USD
Crowley Michael
EVP, GBL Commercial Operations
- 642
305.1 USD
1 year ago
Aug 30, 2023
Sell 154 K USD
ERNST TIMOTHY S
EVP, General Counsel & Sec
- 391
394.16 USD
1 year ago
Aug 30, 2023
Sell 626 K USD
ERNST TIMOTHY S
EVP, General Counsel & Sec
- 1582
395.76 USD
1 year ago
Aug 30, 2023
Sell 149 K USD
ERNST TIMOTHY S
EVP, General Counsel & Sec
- 377
396.44 USD
1 year ago
Aug 23, 2023
Sell 115 K USD
ERNST TIMOTHY S
EVP, General Counsel & Sec
- 300
384.69 USD
1 year ago
Jun 15, 2023
Sell 190 K USD
Crowley Michael
EVP, GBL Commercial Operations
- 500
379.39 USD
1 year ago
Jun 06, 2023
Sell 6.39 K USD
RAMALINGAM AJIT
SVP, Chief Accounting Officer
- 17.352
368.49 USD
1 year ago
Jun 06, 2023
Sell 66.7 K USD
RAMALINGAM AJIT
SVP, Chief Accounting Officer
- 181
368.28 USD
1 year ago
Mar 08, 2023
Sell 486 K USD
ERNST TIMOTHY S
EVP, General Counsel & Sec
- 1000
486.08 USD
1 year ago
Mar 08, 2023
Sell 363 K USD
ERNST TIMOTHY S
EVP, General Counsel & Sec
- 746
486.89 USD
2 years ago
Nov 10, 2022
Sell 113 K USD
RAMALINGAM AJIT
SVP, Chief Accounting Officer
- 267
421.7 USD
2 years ago
Nov 10, 2022
Sell 47.3 K USD
RAMALINGAM AJIT
SVP, Chief Accounting Officer
- 112
422.28 USD
2 years ago
Nov 10, 2022
Sell 161 USD
RAMALINGAM AJIT
SVP, Chief Accounting Officer
- 0.3809
423.61 USD
3 years ago
Nov 11, 2021
Sell 324 K USD
TUMOLO ANNETTE
Executive Vice President
- 433
748.08 USD
3 years ago
Nov 11, 2021
Sell 459 K USD
TUMOLO ANNETTE
Executive Vice President
- 613
748.84 USD
3 years ago
Nov 11, 2021
Sell 375 K USD
TUMOLO ANNETTE
Executive Vice President
- 500
750 USD
3 years ago
Nov 12, 2021
Sell 3.6 M USD
TUMOLO ANNETTE
Executive Vice President
- 4800
750.05 USD
3 years ago
Sep 03, 2021
Sell 221 K USD
Daskal Ilan
EVP, Chief Financial Officer
- 270
820.06 USD
3 years ago
Sep 01, 2021
Sell 609 K USD
Last Andrew J.
EVP, Chief Operating Officer
- 750
812.27 USD
3 years ago
Sep 01, 2021
Sell 529 K USD
Last Andrew J.
EVP, Chief Operating Officer
- 651
813.15 USD
3 years ago
Sep 01, 2021
Sell 488 K USD
Last Andrew J.
EVP, Chief Operating Officer
- 599
814.09 USD
3 years ago
Sep 02, 2021
Sell 364 K USD
Daskal Ilan
EVP, Chief Financial Officer
- 440
828 USD
3 years ago
Sep 02, 2021
Sell 82.8 K USD
Daskal Ilan
EVP, Chief Financial Officer
- 100
828.01 USD
3 years ago
Aug 26, 2021
Sell 476 K USD
TUMOLO ANNETTE
Executive Vice President
- 600
792.58 USD
3 years ago
Aug 09, 2021
Sell 1.94 M USD
Crowley Michael
EVP, GBL Commercial Operations
- 2570
754.8 USD
3 years ago
Aug 09, 2021
Sell 325 K USD
Crowley Michael
EVP, GBL Commercial Operations
- 430
755.72 USD
3 years ago
Aug 04, 2021
Sell 249 K USD
ERNST TIMOTHY S
EVP, General Counsel & Sec
- 327
760.26 USD
3 years ago
Aug 04, 2021
Sell 643 K USD
Daskal Ilan
EVP, Chief Financial Officer
- 857
750.85 USD
3 years ago
Aug 04, 2021
Sell 717 K USD
Daskal Ilan
EVP, Chief Financial Officer
- 954
751.98 USD
3 years ago
Aug 04, 2021
Sell 368 K USD
Daskal Ilan
EVP, Chief Financial Officer
- 489
753.32 USD
3 years ago
Feb 19, 2021
Sell 256 K USD
ERNST TIMOTHY S
EVP, General Counsel & Sec
- 400
640.94 USD
3 years ago
Feb 19, 2021
Sell 210 K USD
ERNST TIMOTHY S
EVP, General Counsel & Sec
- 327
640.92 USD
3 years ago
Feb 19, 2021
Sell 126 K USD
ERNST TIMOTHY S
EVP, General Counsel & Sec
- 196.107
640.17 USD
3 years ago
Dec 15, 2020
Sell 217 K USD
Crowley Michael
EVP, GBL Commercial Operations
- 374
580.67 USD
4 years ago
Nov 06, 2020
Sell 141 K USD
TUMOLO ANNETTE
Executive Vice President
- 220
639.62 USD
4 years ago
Nov 06, 2020
Sell 470 K USD
TUMOLO ANNETTE
Executive Vice President
- 734
640.78 USD
4 years ago
Nov 06, 2020
Sell 158 K USD
TUMOLO ANNETTE
Executive Vice President
- 246
641.53 USD
4 years ago
Aug 19, 2020
Sell 163 K USD
Magni Giovanni
EVP, Chief Strategy Officer
- 315
517.64 USD
4 years ago
Aug 19, 2020
Sell 2.8 M USD
Magni Giovanni
EVP, Chief Strategy Officer
- 5392
518.76 USD
4 years ago
Aug 19, 2020
Sell 589 K USD
Magni Giovanni
EVP, Chief Strategy Officer
- 1133
519.89 USD
4 years ago
Aug 19, 2020
Sell 2.95 M USD
Magni Giovanni
EVP, Chief Strategy Officer
- 5668
520.94 USD
4 years ago
Aug 19, 2020
Sell 177 K USD
Magni Giovanni
EVP, Chief Strategy Officer
- 339
521.86 USD
4 years ago
Jun 01, 2020
Sell 728 K USD
Crowley Michael
EVP, GBL Commercial Operations
- 1500
485.4 USD
4 years ago
May 13, 2020
Sell 203 K USD
HUTTON RONALD W
Vice President and Treasurer
- 443
457.35 USD
4 years ago
Dec 04, 2019
Sell 463 K USD
ERNST TIMOTHY S
EVP, General Counsel & Sec
- 1250
370.11 USD
4 years ago
Dec 04, 2019
Sell 243 K USD
ERNST TIMOTHY S
EVP, General Counsel & Sec
- 656
370.12 USD
5 years ago
Nov 11, 2019
Sell 298 K USD
STARK JAMES R
VP, Corporate Controller
- 848
351.45 USD
5 years ago
Sep 12, 2019
Sell 172 K USD
TUMOLO ANNETTE
Executive Vice President
- 522
330 USD
5 years ago
Sep 12, 2019
Sell 262 K USD
HERTIA JOHN
Executive Vice President
- 797
328.25 USD
5 years ago
Sep 12, 2019
Sell 13.5 K USD
HERTIA JOHN
Executive Vice President
- 41
329 USD
7. News
BIO-key Reports Q3'24 Revenue Rose 18% to $2.1M, Reduced Q3'24 Net Loss, and Improved Cash Position; Hosts Investor Call Tomorrow, Fri. Nov. 15th, 10am ET BIO-key (BKYI) Reports Q3'24 Revenue Rose 18% to $2.1M, Reduced Q3'24 Net Loss, Improved Cash Position; Hosts Conf. Call Tomorrow, Fri. Nov. 15th, 10am ET. globenewswire.com - 2 days ago
BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees MINNEAPOLIS , Nov. 14, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its lineup of presentations and activities for the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, taking place November 19-23 in Vancouver, British Columbia. Asuragen, a Bio-Techne brand, will be exhibiting and showcasing its latest research products for breast cancer monitoring and carrier screening in booth #811. prnewswire.com - 2 days ago
UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS R&D Systems Hematology Controls and Calibrators has completed the Class B Certification under the new European Union In Vitro Diagnostic Regulation This press release updates the IVDR Classification to Class B from the prior Class C.  MINNEAPOLIS , Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. prnewswire.com - 5 days ago
BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS R&D Systems Hematology Controls and Calibrators has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation MINNEAPOLIS , Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the regulations and guidelines set forth by the European Union for in-vitro diagnostic devices. prnewswire.com - 5 days ago
BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES MINNEAPOLIS , Nov. 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: UBS Global Healthcare Conference November 12, 2024 9:30 AM PST Stifel 2024 Healthcare Conference November 19, 2024 8:00 AM EST Stephens NASH 2024 Conference November 20, 2024 11:00 AM CST A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. prnewswire.com - 1 week ago
Interpreting Bio-Rad (BIO) International Revenue Trends Examine the evolution of Bio-Rad's (BIO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects. zacks.com - 1 week ago
Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will participate in the upcoming BIO-Europe 2024 conference in Stockholm. The event will allow Tiziana to engage with industry leaders, potential collaborators, and investors, emphasizing its recent clinical advancements, particularly data from its combination study involving Ozempic, a GLP-1 agonist. proactiveinvestors.com - 2 weeks ago
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference's partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent clinical progress, including data from its combination study involving Ozempic, a GLP-1 agonist. globenewswire.com - 2 weeks ago
BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket Bio-Rad witnesses growth across the Clinical Diagnostics segment in the third quarter, primarily driven by an increased demand for quality control and immunology products. zacks.com - 2 weeks ago
Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the UBS Global Healthcare Conference on Wednesday, November 13, 2024, at 1:15 PM Pacific Time. A live webcast and subsequent replay of the event will be available in th. businesswire.com - 2 weeks ago
Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Norman Schwartz - Chairman of the Board, President & Chief Executive Officer Jon DiVincenzo - President & Chief Operating Officer Roop Lakkaraju - Executive Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Leonard - UBS Brandon Couillard - Wells Fargo Jack Meehan - Nephron Research Tycho Peterson - Jefferies Operator Hello, everyone, and welcome to today's Bio-Rad Third Quarter 2024 Results Conference Call and Webcast. At this time to get started, all participants are in a listen-only mode. seekingalpha.com - 2 weeks ago
Bio-Rad Laboratories (BIO) Beats Q3 Earnings and Revenue Estimates Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $2.33 per share a year ago. zacks.com - 2 weeks ago
8. Profile Summary

Bio-Rad Laboratories, Inc. BIO

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 8.98 B
Dividend Yield 0.17%
Description Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Contact 1000 Alfred Nobel Drive, Hercules, CA, 94547 https://www.bio-rad.com
IPO Date Feb. 27, 1980
Employees 7700
Officers Mr. Yong Chung Vice President of Investor Relations Ms. Colleen Corey Executive Vice President of Global Human Resources Mr. James J. Barry Executive Vice President & President of Life Science Group Mr. Norman D. Schwartz Chairman & Chief Executive Officer Matthew Werner Senior Vice President and Chief Compliance & Privacy Officer Courtney C. Enloe Executive Vice President, General Counsel & Secretary Mr. Jonathan P. DiVincenzo President & Chief Operating Officer Mr. Michael Crowley Executive Vice President of Global Commercial Operations Lee Boyd Senior Vice President of Global Commercial Operations - Asia Pacific Ms. Tania DeVilliers Senior Director, Corporate Controller & Interim Principal Accounting Officer